



The Epigenetics of Autoimmune Diseases

Editor Moncef Zouali

 WILEY-BLACKWELL

Contents

Preface	xiii
Contributors	xvii
PART I Transcription Factors: Partners of Immune Tolerance to Self	
1 Transcriptional regulation of T cell tolerance	3
<i>Brian T. Abe, Ayana Jordan, Vanessa M. Hubbard and Fernando Macian</i>	
1.1 Introduction	3
1.2 T cell anergy	4
1.3 Ca^{2+} /calcineurin/NFAT signalling in T cell anergy	5
1.4 Transcriptional programme of T cell anergy	7
1.5 Transcriptional repression in T cell anergy: epigenetic modification of the <i>Il2</i> promoter	10
1.6 Regulatory T cells	12
1.7 Transcriptional control of Treg development and function	12
References	15
2 Epigenetic regulation of Foxp3 expression in regulatory T cells	21
<i>Julia K. Polansky, Stefan Floess, Jennifer Freyer, Alf Hamann and Jochen Huehn</i>	
2.1 Introduction	21
2.2 Naturally occurring $\text{CD}25^{+}\text{CD}4^{+}$ Tregs	22
2.3 The transcription factor FOXP3: determining Treg function and identity	25
2.4 Molecular regulation of FOXP3	26
2.5 Tregs as a stable lineage: indications of epigenetic imprinting	28
2.6 Induced Tregs: stable suppressors or transient immuno-modulators?	30
2.7 Conclusions	32
References	33
3 The role of NF-κB in central tolerance	39
<i>Mingzhao Zhu, Matthew Ruddy and Yang-Xin Fu</i>	
3.1 Introduction	39
3.2 Canonical and alternative NF- κ B pathways	40

3.3	Thymic stroma and central tolerance	43
3.4	NF- κ B and regulatory T cell development	47
3.5	NF- κ B and thymocyte positive and negative selection	48
3.6	Conclusions and perspectives	50
3.7	Acknowledgement	50
	References	50
4	The role of Act1 in the control of autoimmunity	55
	<i>Trine N. Jørgensen, Natalia V. Giltiay, Angela Johnson and Xiaoxia Li</i>	
4.1	Introduction	55
4.2	Autoimmunity and autoimmune mouse models	56
4.3	Molecular mechanisms of autoimmunity	58
4.4	Act1: a modulator of autoimmunity	60
4.5	Conclusions	70
	References	71
5	Regulation of T cell anergy and escape from regulatory T cell suppression by Cbl-b	75
	<i>Stefanie Loeser and Josef M. Penninger</i>	
5.1	Introduction	75
5.2	Mechanisms of T cell tolerance induction	75
5.3	Molecular establishment of T cell anergy	78
5.4	Ubiquitin E3 ligases in T cell tolerance	79
5.5	Molecular function and regulation of Cbl-b	80
5.6	Physiological relevance of Cbl-b	83
5.7	The role of Cbl-b in T cell tolerance	84
5.8	Deregulation of Cbl-b in disease	86
5.9	Therapeutic potential of Cbl-b in tumour immunity	86
5.10	Implications for autoimmune disease	88
	References	88
6	Indoleamine 2,3-dioxygenase: transcriptional regulation and autoimmunity	95
	<i>Maria Laura Belladonna, Ciriana Orabona, Claudia Volpi, Ursula Grahmann, Paolo Puccetti and Maria Cristina Fioretti</i>	
6.1	Introduction	95
6.2	L-Trp degradation along the kynurenine pathway and immune functions of IDO	96
6.3	IDO immunobiology and therapeutic intervention	101
6.4	Transcriptional regulation of the IDO-encoding gene	101
6.5	Impaired IDO activity and loss of tolerance in autoimmune diseases	107
6.6	IDO-based therapies for autoimmune disease	109
6.7	Acknowledgement	110
	References	111

PART II Stress Responses that Break Immune Silence

7	Chromatin modifications, oxidative stress and nucleosome autoantibodies	119
	<i>Annika Erbacher and Patrice Decker</i>	
7.1	Introduction	119
7.2	Nucleosome and SLE	120
7.3	Epigenetics and SLE	123
7.4	Oxidative stress in SLE: definition and mechanisms	124
7.5	Oxidative stress, epigenetic alterations and nucleosome immunogenicity	127
7.6	Conclusion	129
7.7	Acknowledgements	129
	References	130
8	Stress, epigenetics and thyroid autoimmunity	135
	<i>Agathocles Tsatsoulis</i>	
8.1	Introduction	135
8.2	The Th1/Th2 balance in immune-response regulation	136
8.3	Stress hormones and the Th1/Th2 balance	136
8.4	The Th1/Th2 balance in thyroid autoimmunity	138
8.5	Association of stress with thyroid autoimmunity	140
8.6	Stress in the clinical expression of thyroid autoimmunity: a unifying hypothesis	143
8.7	Epigenetic regulation of T cell differentiation and stress hormones	145
8.8	Conclusions	146
	References	146
9	Reactive intermediates, inflammation and epigenetics in lupus	151
	<i>Gary S. Gilkeson and Jim C. Oates</i>	
9.1	Introduction	151
9.2	Biology of reactive intermediates	151
9.3	RNIs in murine models of lupus	155
9.4	Genetic associations of RNI/ROI and lupus	159
9.5	Conclusions	160
	References	160
10	Post-translational modification of HMGB1 and its role in immune activation	165
	<i>Anirudh J. Ullal and David S. Pisetsky</i>	
10.1	Introduction	165
10.2	Molecular biology of HMGB1	166
10.3	HMGB1 as an immune mediator	167

10.4	Mechanisms of HMGB1 modification and release	169
10.5	The role of HMGB1 as a mediator of disease and target of therapy	172
10.6	Conclusion	174
	References	174
11	Idiosyncratic drug-induced liver injury: facts and perspectives	179
	<i>José V. Castell and Isabel Miñana</i>	
11.1	Introduction	179
11.2	Intrinsic drug toxicity to the liver	179
11.3	Idiosyncratic drug toxicity to the liver	180
11.4	Mechanisms of hypersensitivity reactions to drugs in the liver	182
11.5	Hypersensitivity versus tolerance	187
11.6	Hepatocyte injury as a consequence of allergic hepatitis	192
11.7	Drug-induced liver autoimmunity	194
11.8	Epigenetics of drug-induced liver injury	197
11.9	Acknowledgements	199
	References	199
 PART III Epigenetic Modifiers of Autoimmunity		
12	Epigenetic modifications associated with T cell tolerance	209
	<i>Andrew D. Wells and Rajan M. Thomas</i>	
12.1	Immunity versus tolerance	209
12.2	Epigenetic regulation of the physical structure of genomic DNA	209
12.3	Epigenetic control of pro-inflammatory cytokine gene transcription	211
12.4	Epigenetic silencing of cytokine genes in tolerant T cells	213
12.5	Targeting epigenetic modifications to cytokine genes in tolerant T cells	217
12.6	Common mechanisms of epigenetic silencing among distinct types of tolerant T cells?	220
	References	220
13	DNA methylation alterations in systemic lupus erythematosus	229
	<i>Biola M. Javierre, Manel Esteller and Esteban Ballestar</i>	
13.1	Introduction	229
13.2	DNA methylation: an epigenetic determinant of lymphocyte function	233
13.3	DNA methylation changes in lupus	235
13.4	Epigenetic regulation as a therapeutic target	240
13.5	Future aims for epigenetic research into lupus	241
13.6	Acknowledgements	242
	References	242

14	Long-range histone acetylation patterns in the development of autoimmunity	247
	<i>Thomas M. Aune, Shaojing Chang and Weisong Zhou</i>	
14.1	Introduction	247
14.2	The histone code hypothesis	247
14.3	Epigenetic defects as a mechanism of disease	249
14.4	Analysis of the histone code	250
14.5	Long-range histone acetylation patterns in Th cell differentiation	251
14.6	Long-range histone acetylation and autoimmunity	253
14.7	Perspectives	256
14.8	Acknowledgements	257
	References	257
15	Roquin defects reveal a role for the microRNA machinery in regulating autoimmunity	261
	<i>Di Yu and Carola G. Vinuesa</i>	
15.1	Introduction	261
15.2	RNA silencing through the miRNA machinery	262
15.3	miRNAs regulate lymphoid cell development and immune responses	263
15.4	miRNAs as single drivers of immunodeficiency or inflammation	264
15.5	miRNAs regulate autoimmunity	265
15.6	Roquin regulates miRNA-mediated silencing of T cells and represses lupus	266
15.7	Concluding remarks	272
15.8	Acknowledgements	273
	References	274
16	Autoimmune response to post-translationally modified (citrullinated) proteins: prime suspect in the pathophysiology of rheumatoid arthritis	279
	<i>Mireille Sebbag, Cyril Clavel, Leonor Nogueira, Jacques Arnaud and Guy Serre</i>	
16.1	Introduction	279
16.2	RA is associated with B cell autoreactivity to citrullinated proteins	280
16.3	Both ACPA and citrullinated antigenic targets are present in the RA synovium	284
16.4	Autoreactivity to citrullinated proteins probably plays a role in RA synovitis	285
16.5	The way ACPA could promote joint inflammation	286
16.6	Joint-expressed citrullinated autoantigen targets possibly involved in a pro-inflammatory effect of ACPA	287
16.7	Initial triggering of the autoimmune response to citrullinated proteins	291
16.8	Goals for future research	297
16.9	Acknowledgements	298
	References	298

17	Hormones: epigenetic contributors to gender-biased autoimmunity	309
	<i>Virginia Rider and Nabih I. Abdou</i>	
17.1	Introduction	309
17.2	Oestrogen receptors	309
17.3	Oestrogen and autoimmunity	310
17.4	Foxp3 and ERs	312
17.5	ERs and histone modifications	313
17.6	The histone code	313
17.7	Co-activators	314
17.8	Pioneer factors	314
17.9	Co-repressors	315
17.10	ERs and cell proliferation	315
17.11	Epigenetic changes in disease	315
17.12	ERs and SLE	316
17.13	Co-activators and phosphorylation	317
17.14	Endocrine disruptors	318
17.15	Perspectives and future directions	318
17.16	Acknowledgements	320
	References	321
18	Epigenetics and systemic sclerosis	327
	<i>Serena Guiducci and Marco Matucci Cerinic</i>	
18.1	Introduction	327
18.2	Vascular alterations in SSc	328
18.3	Tissue hypoxia, oxidative stress and SSc	329
18.4	Respiratory burst and post-translational modifications in SSc	330
18.5	The epigenome and its environmental reprogramming	331
18.6	Epigenetics and SSc	332
18.7	Conclusions	334
	References	335
19	Epigenetic regulation of B lymphocyte development and repertoire selection: relevance to autoimmunity	339
	<i>Moncef Zouali</i>	
19.1	Introduction	339
19.2	Initiation of B cell fate choice	340
19.3	Checkpoints of B cell tolerance to self	340
19.4	Negative regulation of immunoglobulin gene joining	342
19.5	B cell fate commitment and immunoglobulin gene accessibility	343
19.6	Changes in chromatin structure during B cell development	344
19.7	Epigenetic changes through association of different immunoglobulin loci	346
19.8	Epigenetic factors that allow full utilization of the immunoglobulin repertoire	347

19.9	Multistep regulation of B cell maturation	348
19.10	Altered B cell functions in systemic autoimmunity	349
19.11	Impaired B cell tolerance to self in systemic autoimmunity	350
19.12	Epigenetic factors underlying impaired B cell tolerance	351
19.13	Future prospects	352
19.14	Acknowledgement	353
	References	353

PART IV Towards Novel Epigenetic-Based Immuno-Intervention Strategies in Autoimmune Disease

20	Protective effects of epigenetic modifications in experimental inflammatory bowel disease	359
	<i>Rainer Glauben, Elena Sonnenberg and Britta Siegmund</i>	
20.1	Introduction	359
20.2	Mechanisms of protein acetylation and deacetylation	360
20.3	Anti-inflammatory effect of epigenetic modifications <i>in vitro</i>	362
20.4	Impact of HDAC inhibition in models of experimental colitis	365
20.5	Perspectives	368
	References	369
21	Epigenetic regulation of autoimmune diseases through deacetylase inhibition	373
	<i>Bin Li, Yuan Shen, Zhaocai Zhou, Xiaomin Song, Kathryn Bembas, Xiao Yun Zhao, Zheng Cai, Alan Berezov, Sandra J. Saouaf, Hongtao Zhang, Qiang Wang and Mark I. Greene</i>	
21.1	Introduction	373
21.2	Regulatory T cells	374
21.3	Epigenetic regulation of <i>FOXP3</i> expression	375
21.4	<i>FOXP3</i> acetylation and function	375
21.5	Protein lysine deacetylation	376
21.6	HDAC inhibitors in autoimmune disease	377
21.7	Dietary butyrate promotes lysine acetylation by inhibiting deacetylases	378
21.8	The HDAC inhibitor butyrate affects TGF- β signalling and increases Smad3 levels	378
21.9	HDAC inhibitors affect immune-cell proliferation and conversion of antigen triggered T cells into an unresponsive state	378
21.10	Conclusions	379
	References	380
22	Histone deacetylases and autoimmunity	385
	<i>András Treszl, Gergő Mészáros, Gergely Toldi and Barna Vásárhelyi</i>	
22.1	Introduction	385
22.2	Chromatin acetylation and deacetylation	385

22.3	Histone deacetylases and histone acetyltransferases	386
22.4	Histone acetylation, deacetylation and transcription factors in autoimmunity	389
22.5	Acetylation state and lymphocyte functions	392
22.6	HDACs and their inhibition in autoimmune disease	393
22.7	Conclusions	398
22.8	Acknowledgements	398
	References	398
23	Histone deacetylase inhibitors as a therapeutic modality in multiple sclerosis	403
	<i>Steven G. Gray</i>	
23.1	Introduction	403
23.2	Linking the histone code with MS	404
23.3	Neuronal traits are modulated by HDAC transcription-factor complexes	405
23.4	Motor neurone genes modulated by HDACs	406
23.5	The transcription factor E2F1, HDACs and neuronal survival mechanisms	406
23.6	HDACs play important roles in stem cell neuronal differentiation	407
23.7	HDIs lead to acetylation of the Sp1 transcription factor	407
23.8	Immune-system effects of HDIs	408
23.9	HDACs and pro-inflammatory and stress-related pathways in immune settings	411
23.10	HATs, HDACs and the NF- κ B pathway	411
23.11	HATs, HDACs and ER stress	414
23.12	Clinical trials and caveats of HDIs	415
23.13	Do HDIs target genes or help chaperone activity as their primary response?	417
23.14	Future directions	418
	References	419
	Index	433